# Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus

> **NCT01408576** · PHASE3 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 1250 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** Epratuzumab
- **DRUG:** Epratuzumab

## Key facts

- **NCT ID:** NCT01408576
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 1250 (ACTUAL)
- **Last updated:** 2018-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01408576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01408576, "Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01408576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*